Cargando…

Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning

PURPOSE: Consolidation immunotherapy after completion of chemoradiotherapy has become the standard of care for unresectable locally advanced non‐small cell lung cancer and can induce potentially severe and life‐threatening adverse events, including both immune checkpoint inhibitor‐related pneumoniti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Jun, Pan, Yi, Huang, Wei, Huang, Kun, Cui, Yanhai, Hong, Wenhui, Wang, Lingling, Ni, Dong, Tan, Peixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306809/
https://www.ncbi.nlm.nih.gov/pubmed/35026041
http://dx.doi.org/10.1002/mp.15451
_version_ 1784752623439577088
author Cheng, Jun
Pan, Yi
Huang, Wei
Huang, Kun
Cui, Yanhai
Hong, Wenhui
Wang, Lingling
Ni, Dong
Tan, Peixin
author_facet Cheng, Jun
Pan, Yi
Huang, Wei
Huang, Kun
Cui, Yanhai
Hong, Wenhui
Wang, Lingling
Ni, Dong
Tan, Peixin
author_sort Cheng, Jun
collection PubMed
description PURPOSE: Consolidation immunotherapy after completion of chemoradiotherapy has become the standard of care for unresectable locally advanced non‐small cell lung cancer and can induce potentially severe and life‐threatening adverse events, including both immune checkpoint inhibitor‐related pneumonitis (CIP) and radiation pneumonitis (RP), which are very challenging for radiologists to diagnose. Differentiating between CIP and RP has significant implications for clinical management such as the treatments for pneumonitis and the decision to continue or restart immunotherapy. The purpose of this study is to differentiate between CIP and RP by a CT radiomics approach. METHODS: We retrospectively collected the CT images and clinical information of patients with pneumonitis who received immune checkpoint inhibitor (ICI) only (n = 28), radiotherapy (RT) only (n = 31), and ICI+RT (n = 14). Three kinds of radiomic features (intensity histogram, gray‐level co‐occurrence matrix [GLCM] based, and bag‐of‐words [BoW] features) were extracted from CT images, which characterize tissue texture at different scales. Classification models, including logistic regression, random forest, and linear SVM, were first developed and tested in patients who received ICI or RT only with 10‐fold cross‐validation and further tested in patients who received ICI+RT using clinicians’ diagnosis as a reference. RESULTS: Using 10‐fold cross‐validation, the classification models built on the intensity histogram features, GLCM‐based features, and BoW features achieved an area under curve (AUC) of 0.765, 0.848, and 0.937, respectively. The best model was then applied to the patients receiving combination treatment, achieving an AUC of 0.896. CONCLUSIONS: This study demonstrates the promising potential of radiomic analysis of CT images for differentiating between CIP and RP in lung cancer, which could be a useful tool to attribute the cause of pneumonitis in patients who receive both ICI and RT.
format Online
Article
Text
id pubmed-9306809
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93068092022-07-28 Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning Cheng, Jun Pan, Yi Huang, Wei Huang, Kun Cui, Yanhai Hong, Wenhui Wang, Lingling Ni, Dong Tan, Peixin Med Phys QUANTITATIVE IMAGING AND IMAGE PROCESSING PURPOSE: Consolidation immunotherapy after completion of chemoradiotherapy has become the standard of care for unresectable locally advanced non‐small cell lung cancer and can induce potentially severe and life‐threatening adverse events, including both immune checkpoint inhibitor‐related pneumonitis (CIP) and radiation pneumonitis (RP), which are very challenging for radiologists to diagnose. Differentiating between CIP and RP has significant implications for clinical management such as the treatments for pneumonitis and the decision to continue or restart immunotherapy. The purpose of this study is to differentiate between CIP and RP by a CT radiomics approach. METHODS: We retrospectively collected the CT images and clinical information of patients with pneumonitis who received immune checkpoint inhibitor (ICI) only (n = 28), radiotherapy (RT) only (n = 31), and ICI+RT (n = 14). Three kinds of radiomic features (intensity histogram, gray‐level co‐occurrence matrix [GLCM] based, and bag‐of‐words [BoW] features) were extracted from CT images, which characterize tissue texture at different scales. Classification models, including logistic regression, random forest, and linear SVM, were first developed and tested in patients who received ICI or RT only with 10‐fold cross‐validation and further tested in patients who received ICI+RT using clinicians’ diagnosis as a reference. RESULTS: Using 10‐fold cross‐validation, the classification models built on the intensity histogram features, GLCM‐based features, and BoW features achieved an area under curve (AUC) of 0.765, 0.848, and 0.937, respectively. The best model was then applied to the patients receiving combination treatment, achieving an AUC of 0.896. CONCLUSIONS: This study demonstrates the promising potential of radiomic analysis of CT images for differentiating between CIP and RP in lung cancer, which could be a useful tool to attribute the cause of pneumonitis in patients who receive both ICI and RT. John Wiley and Sons Inc. 2022-01-27 2022-03 /pmc/articles/PMC9306809/ /pubmed/35026041 http://dx.doi.org/10.1002/mp.15451 Text en © 2022 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle QUANTITATIVE IMAGING AND IMAGE PROCESSING
Cheng, Jun
Pan, Yi
Huang, Wei
Huang, Kun
Cui, Yanhai
Hong, Wenhui
Wang, Lingling
Ni, Dong
Tan, Peixin
Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning
title Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning
title_full Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning
title_fullStr Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning
title_full_unstemmed Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning
title_short Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning
title_sort differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by ct radiomics and machine learning
topic QUANTITATIVE IMAGING AND IMAGE PROCESSING
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306809/
https://www.ncbi.nlm.nih.gov/pubmed/35026041
http://dx.doi.org/10.1002/mp.15451
work_keys_str_mv AT chengjun differentiationbetweenimmunecheckpointinhibitorrelatedandradiationpneumonitisinlungcancerbyctradiomicsandmachinelearning
AT panyi differentiationbetweenimmunecheckpointinhibitorrelatedandradiationpneumonitisinlungcancerbyctradiomicsandmachinelearning
AT huangwei differentiationbetweenimmunecheckpointinhibitorrelatedandradiationpneumonitisinlungcancerbyctradiomicsandmachinelearning
AT huangkun differentiationbetweenimmunecheckpointinhibitorrelatedandradiationpneumonitisinlungcancerbyctradiomicsandmachinelearning
AT cuiyanhai differentiationbetweenimmunecheckpointinhibitorrelatedandradiationpneumonitisinlungcancerbyctradiomicsandmachinelearning
AT hongwenhui differentiationbetweenimmunecheckpointinhibitorrelatedandradiationpneumonitisinlungcancerbyctradiomicsandmachinelearning
AT wanglingling differentiationbetweenimmunecheckpointinhibitorrelatedandradiationpneumonitisinlungcancerbyctradiomicsandmachinelearning
AT nidong differentiationbetweenimmunecheckpointinhibitorrelatedandradiationpneumonitisinlungcancerbyctradiomicsandmachinelearning
AT tanpeixin differentiationbetweenimmunecheckpointinhibitorrelatedandradiationpneumonitisinlungcancerbyctradiomicsandmachinelearning